Le Lézard
Classified in: Health
Subject: SVY

The global market for viral vector vaccines is expected to grow at a CAGR of 18.19% over the forecast period of 2019-2027


NEW YORK, Oct. 18, 2018 /PRNewswire/ -- KEY FINDINGS
The global market for viral vector vaccines is expected to grow at a CAGR of 18.19% over the forecast period of 2019-2027. Promising results from several clinical studies performed by various organizations have emphasized the potential of viral-vector-based vaccines and therapies for gene therapies.

Read the full report: https://www.reportlinker.com/p05591510

MARKET INSIGHTS
The global market for viral vector vaccines is segmented on the basis of types, applications and diseases.The global viral vector vaccine manufacturing market by type segment comprises adenoviral vectors, retroviral vectors, lentivirus vectors, adeno-associated viral vectors, cytomegalovirus, and other viral vectors.

Key strategic initiatives being undertaken by companies to expand their viral vector manufacturing capabilities are also expected to drive notable growth across the global viral vector vaccine manufacturing market over the forecast period.

REGIONAL INSIGHTS
Geographically the global viral vector vaccine manufacturing market has been segmented into North America, Europe, Asia-Pacific and Rest of the World.Among these regions, the European market holds the largest share.

The reason for this can possibly be a rise in the livestock diseases in the region, which is fueling the market for viral vector vaccine manufacturing as these viral-vectors-based vaccines are highly adapted for the prevention of livestock diseases. Heavy investment in related R&D is also expected to increase the vaccine production capacity.

COMPETITIVE INSIGHTS
Leading market players in the global viral vector vaccines manufacturing market are Advanced Biotherapeutics Consulting, Advanced Bioscience Laboratories Inc., Applied Viromics, Batavia Biosciences, Benitec Biopharma, Biogen Idec (Now Biogen Inc.), Biovian, Brammer Bio, Boehringer Ingelheim Gmbh, Cell and Gene Therapy Catapult, Ceva Corporate, Cobra Biologics (Subsidiary Of Recip Ab), Ge Healthcare, Janssen Pharmaceutical Inc. and ID Pharma Co. Ltd.

Companies mentioned
1. ADVANCED BIOTHERAPEUTICS CONSULTING
2. ADVANCED BIOSCIENCE LABORATORIES INC.
3. APPLIED VIROMICS
4. BATAVIA BIOSCIENCES
5. BENITEC BIOPHARMA
6. BIOGEN IDEC (NOW BIOGEN INC.)
7. BIOVIAN
8. BRAMMER BIO
9. BOEHRINGER INGELHEIM GMBH
10. CELL AND GENE THERAPY CATAPULT
11. CEVA CORPORATE
12. COBRA BIOLOGICS (SUBSIDIARY OF RECIP AB)
13. GE HEALTHCARE
14. JANSSEN PHARMACEUTICAL INC.
15. ID PHARMA CO. LTD.

Read the full report: https://www.reportlinker.com/p05591510

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 22:54
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

at 22:03
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

at 20:35
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

at 19:05
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIOŽ (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
Media Advisory - Minister Saks in Winnipeg to highlight Budget 2024: Fairness for Every Generation investments to boost research funding in Canada
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 18:18
Targeting A Solution Panel Aims to Find Solutions for the Veteran Suicide Crisis with National Thought Leaders Tulsi Gabbard, Tim Kennedy, and Dan Hollaway
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...

More news about Health...


News published on and distributed by: